Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/52787
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJessica M. Fogelen_US
dc.contributor.authorLei Wangen_US
dc.contributor.authorTeresa L. Parsonsen_US
dc.contributor.authorSan San Ouen_US
dc.contributor.authorEstelle Piwowar-Manningen_US
dc.contributor.authorYing Chenen_US
dc.contributor.authorVictor O. Mudhuneen_US
dc.contributor.authorMina C. Hosseinipouren_US
dc.contributor.authorJohnstone Kumwendaen_US
dc.contributor.authorJames G. Hakimen_US
dc.contributor.authorSuwat Chariyalertsaken_US
dc.contributor.authorRavindre Panchiaen_US
dc.contributor.authorIan Sanneen_US
dc.contributor.authorNagalingeswaran Kumarasamyen_US
dc.contributor.authorBeatriz Grinsztejnen_US
dc.contributor.authorJoseph Makhemaen_US
dc.contributor.authorJose Pilottoen_US
dc.contributor.authorBreno R. Santosen_US
dc.contributor.authorKenneth H. Mayeren_US
dc.contributor.authorMarybeth McCauleyen_US
dc.contributor.authorTheresa Gambleen_US
dc.contributor.authorNamandjé N. Bumpusen_US
dc.contributor.authorCraig W. Hendrixen_US
dc.contributor.authorMyron S. Cohenen_US
dc.contributor.authorSusan H. Eshlemanen_US
dc.date.accessioned2018-09-04T09:32:20Z-
dc.date.available2018-09-04T09:32:20Z-
dc.date.issued2013-11-15en_US
dc.identifier.issn00221899en_US
dc.identifier.other2-s2.0-84888605119en_US
dc.identifier.other10.1093/infdis/jit390en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84888605119&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/52787-
dc.description.abstractThe HIV Prevention Trials Network 052 study enrolled serodiscordant couples. Index participants infected with human immunodeficiency virus reported no prior antiretroviral (ARV) treatment at enrollment. ARV drug testing was performed retrospectively using enrollment samples from a subset of index participants. ARV drugs were detected in 45 of 96 participants (46.9%) with an undetectable viral load, 2 of 48 (4.2%) with a low viral load, and 1 of 65 (1.5%) with a high viral load (P < .0001); they were also detected in follow-up samples from participants who were not receiving study-administered treatment. ARV drug testing may be useful in addition to selfreport of ARV drug use in some clinical trial settings. © The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.en_US
dc.subjectMedicineen_US
dc.titleUndisclosed antiretroviral drug use in a multinational clinical trial (HIV prevention trials network 052)en_US
dc.typeJournalen_US
article.title.sourcetitleJournal of Infectious Diseasesen_US
article.volume208en_US
article.stream.affiliationsThe Johns Hopkins School of Medicineen_US
article.stream.affiliationsFred Hutchinson Cancer Research Centeren_US
article.stream.affiliationsDepartment of Fenway Healthen_US
article.stream.affiliationsFHI 360en_US
article.stream.affiliationsFHI 360en_US
article.stream.affiliationsThe University of North Carolina at Chapel Hillen_US
article.stream.affiliationsKEMRI-CDC HIV Research Branchen_US
article.stream.affiliationsKamuzu Central Hospitalen_US
article.stream.affiliationsCollege of Medicine Blantyreen_US
article.stream.affiliationsGodfrey Huggins School of Medicineen_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsUniversity of Witwatersranden_US
article.stream.affiliationsY R Gaitonade Center for AIDS Research and Educationen_US
article.stream.affiliationsFundacao Oswaldo Cruzen_US
article.stream.affiliationsHospital Geral de Rio de Janeiroen_US
article.stream.affiliationsHospital Nossa Senhora da Conceicaoen_US
article.stream.affiliationsBotswana Harvard School of Public Health AIDS Initiative Partnershipen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.